Cervical Cancer

Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Nventa Biopharmaceuticals Corporation (TSX: NVN) announced positive immunological data from the third cohort of its ongoing Phase 1 clinical trial of its lead product candidate, HspE7, in patients with cervical intraepithelial neoplasia, or CIN, a precursor to cervical cancer.

Better Screening, Treatment, And Affordable Vaccines Can Prevent Doubling Of Cervical Cancer Deaths In Latin America, Caribbean
33,000 women in Latin America and the Caribbean die each year of preventable cervical cancer, caused by a virus that infects 20 percent of men and women in the region and as many as 30 percent of the youngest women, according to a new study.

Gen-Probe Launches In Europe CE-Marked APTIMA(R) HPV Assay For Detection Of Human Papillomavirus
Gen-Probe Incorporated (Nasdaq: GPRO) announced that the Company has launched in Europe its APTIMA(R) HPV Assay, a highly specific molecular diagnostic test to detect high-risk strains of the human papillomavirus (HPV), which causes cervical cancer. The APTIMA HPV Assay has been CE marked and is currently available for sale in 13 European Union countries.

BASHH Expresses Disappointment That The Government Missed The Chance To Eradicate Genital Warts From The Medical Map
The British Association for Sexual Health and HIV (BASHH) today expressed disappointment that the Government has missed the opportunity to eradicate a common STI, genital warts, from the medical map, as today's announcement by the Department of Health on the human papillomavirus vaccine (HPV), "Department of Health awards contract for HPV vaccine", saw GlaxoSmithKline's vaccine Ceravix awarded the Government contract.

Cervical Cancer Screenings Lacking In Developing Countries
A study published in the open-access journal PLoS Medicinehas found that women in the developing world are not getting thecervical cancer screenings that they need. Researcher Emmanuela Gakidou(University of Washington, Seattle, USA) and colleagues report thatalthough women in the developing world have the highest risk ofdeveloping cervical cancer, few are effectively screened.

Cervarix(TM) Provides Longest Duration Of Sustained Neutralising Antibodies Reported For Any Vaccine Against HPV 16 And 18 Date
New data from an extended follow-up study show that CervarixTM generates sustained high levels of neutralising antibodies against the two most common cervical cancer-causing virus types for up to 6.4 years.4 This is the longest duration of sustained neutralising antibody levels reported against both virus types HPV 16 and 18 with a cervical cancer vaccine to date.

Cervarix(TM) Provides Longest Duration Of Sustained Neutralising Antibodies Reported For Any Vaccine Against HPV 16 And 18 Date
New data from an extended follow-up study show that CervarixTM generates sustained high levels of neutralising antibodies against the two most common cervical cancer-causing virus types for up to 6.4 years.4 This is the longest duration of sustained neutralising antibody levels reported against both virus types HPV 16 and 18 with a cervical cancer vaccine to date.

Health Discovery Corporation And DCL Medical Laboratories To Develop A Computer Assisted Diagnostic Test For Cervical Cancer
Health Discovery Corporation (OTCBB: HDVY), a leader in support vector machine (SVM) based molecular diagnostics development, and DCL Medical Laboratories LLC, Indianapolis, IN, a full-service clinical reference laboratory focused on women's health, today announced the signing of a Letter of Intent for the companies to jointly develop an SVM-based computer assisted diagnostic (CAD) test for the analysis of cervical cells.

HPV Vaccine Can Save Lives - Brook Welcomes Details Of The Vaccination Programme, UK
Responding to the announcement by the Department of Health of details of the human papillomavirus (HPV) vaccination programme Simon Blake, Chief Executive of Brook, said: "Brook welcomes confirmation of the details of the HPV vaccination programme from September 2008 that will offer all girls aged 12-13 years vaccination against HPV viruses 16 and 18, the types that lead to increased risk of cervical cancer.

Ending Cervical Cancer Featured At Summit; QIAGEN CEO Issues A Call To Global Women Leaders
QIAGEN was featured this week for its efforts to eliminate cervical cancer at the 14th annual Global Summit of Women in Hanoi, Vietnam. CEO Peer Schatz came to this prominent international platform to issue a call to other leaders in business, NGOs and governments to join him and campaign to create a cervical-cancer-free world.

Safety Concerns Over Merck's HPV Vaccine Gardasil Unfounded, CDC Officials Say
Safety concerns over Merck's human papillomavirus vaccine Gardasil are unfounded, and reports of serious adverse events are unrelated to the vaccine, CDC officials recently said, the Dallas Morning News reports.

Mothers More Willing To Have Older Daughters Vaccinated Against HPV, Study Finds
Although CDC recommends that girls receive the human papillomavirus vaccine at age 11 or 12 to protect against cervical cancer before the onset of sexual activity, mothers of girls under age 13 are less willing to have their daughters vaccinated than mothers of older girls, a new study has found, the